Check out these key findings about Inozyme Pharma Inc (INZY)

With 0.63 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.46 million shares. The 52-week range on INZY shows that it touched its highest point at $7.33 and its lowest point at $2.51 during that stretch. It currently has a 1-year price target of $21.00. Beta for the stock currently stands at 1.34.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of INZY was up-trending over the past week, with a rise of 14.71%, but this was up by 19.09% over a month. Three-month performance surged to 77.51% while six-month performance rose 31.79%. The stock gained 115.46% in the past year, while it has gained 53.76% so far this year. A look at the trailing 12-month EPS for INZY yields -1.50 with Next year EPS estimates of -1.34. For the next quarter, that number is -0.32. This implies an EPS growth rate of 24.48% for this year and 0.21% for next year. EPS is expected to grow by 13.10% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -56.24%.

Float and Shares Shorts:

At present, 61.76 million INZY shares are outstanding with a float of 41.15 million shares on hand for trading. On Feb 15, 2024, short shares totaled 2.4 million, which was 3.88% higher than short shares on Jan 12, 2024. In addition to INCY as the firm’s Incyte Corporation, INFY serves as its Infosys Limited.

Institutional Ownership:

Through their ownership of 92.74% of INZY’s outstanding shares, institutional investors have majority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for INZY since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.

Dividends & Yield:

In terms of dividends, INZY has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and INZY currently yields $0.00. In the past year, INZY’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, INZY has a current buyback yield of $–. This was $– for the TTM, and it was $– for the past five years.

Summary of Insider Activity:

Insiders traded INZY stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 11 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 2,455,904 while 0 shares were sold.